Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Editor, Pharma Insights
UK
37+ years of experience
Pink Sheet
By Ian Schofield 08 Apr 2021
The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.
Generics Bulletin
By Ian Schofield 27 Nov 2020
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
Topic Coronavirus Distribution
Medtech Insight
By Ian Schofield 27 Nov 2020
As negotiators struggle to reach agreement on the future UK/EU relationship following Brexit, suppliers have been warned to expect major hold-ups next year for medical products crossing the English Channel.
Pink Sheet
By Ian Schofield 23 Nov 2020
The UK medicines regulator has written to pharmaceutical companies outlining the actions they need to take regarding products with a centralized EU approval that will be converted to Great Britain marketing authorizations next year.
Topic Pharma-Brexit Brexit Approvals
Pink Sheet
By Ian Schofield 17 Nov 2020
Following a Brexit-induced delay over the summer, England's HTA body NICE has come up with a concrete set of proposals that it says will help it “robustly and efficiently” evaluate innovative technologies such as advanced therapies, histology-independent cancer treatments, and technologies for rare diseases. Industry bodies have welcomed the plans, which have just been put out for consultation.
Pink Sheet
By Ian Schofield 29 Oct 2020
Proposals from NICE now under consultation are intended to boost the health technology assessment body’s efficiency, improve transparency and governance, and raise the quality of its guidance
Topic Regulation EU
Pink Sheet
By Ian Schofield 09 Oct 2020
Delegates at this week’s TOPRA conference heard the European Commission’s “holistic” vision of what it would like to achieve through its pharmaceutical strategy, including incentives for innovation, security of the supply chain, product shortages, real world evidence and big data, and the availability and affordability of medicines.
Pink Sheet
By Ian Schofield 02 Oct 2020
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
Topic Policy & Regulation Brexit
Generics Bulletin
By Ian Schofield 25 Sep 2020
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
Pink Sheet
By Ian Schofield 26 Aug 2020
As the UK prepares to leave the EU, the life sciences industry has urged the government to seek the maximum regulatory alignment and cooperation with the EU. But time is tight, there is much to do, and the industry may struggle to get its voice heard.
Topic Regulation Brexit
Pink Sheet
By Ian Schofield 26 Aug 2020
Brexit and the NHS are likely to be key issues as political parties in the UK prepare to campaign ahead of the general election in December.
Topic Pharma-Brexit Reimbursement
Medtech Insight
By Ian Schofield 28 Apr 2020
A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 diagnostics, vaccines and medicines and to make sure they reach all those who need them.
Topic Coronavirus
Pink Sheet
By Ian Schofield 15 Jan 2020
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
Scrip
By Ian Schofield 12 Jul 2019
The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.
Topic Clinical Trials Approvals
Pink Sheet
By Ian Schofield 11 Jun 2019
Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
Pink Sheet
15 Jul 2022
Pink Sheet
13 Jul 2022
Pink Sheet
12 Jul 2022
Pink Sheet
01 Jul 2022
Pink Sheet
30 Jun 2022
Pink Sheet
29 Jun 2022
Pink Sheet
28 Jun 2022
Pink Sheet
27 Jun 2022
Pink Sheet
22 Jun 2022
Pink Sheet
15 Jun 2022
Pink Sheet
14 Jun 2022
Pink Sheet
13 Jun 2022
Pink Sheet
30 May 2022
Pink Sheet
27 May 2022
Pink Sheet
24 May 2022
